Susquehanna initiates coverage on Optimer Pharmaceuticals (Nasdaq: OPTR) with a Neutral.

Susquehanna analyst says, "Optimer has two late-stage ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE